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6INTRODUCTION
Irritable bowel syndrome (IBS) is a functional bowel disorder in 
which abdominal pain or discomfort is associated with defecation or a 
change in bowel habit. Bloating, distension, and disordered defecation are 
commonly associated features.
IBS is a common condition, affecting approximately 3% to 15% of 
the general population based on various diagnostic criteria. There seem to 
be  differences  in  disease  epidemiology  between  the  eastern  and  the 
western world. As data from larger Asian epidemiological studies begin 
to surface, however, such differences appear to be less marked.
Irritable bowel syndrome is a relapsing functional bowel disorder 
defined  by  symptom-based  diagnostic  criteria,  in  the  absence  of 
detectable organic causes. The symptomatic array is not specific for IBS, 
as  such  symptoms  may  be  experienced  occasionally  by  almost  every 
individual.  To distinguish IBS from transient gut symptoms, experts have 
underscored the chronic and relapsing nature of IBS and have proposed 
diagnostic criteria based on the occurrence rate of symptoms.
The global picture of IBS prevalence is far from complete, with no 
data  available  from  several  regions.(1)  The  prevalence  of  IBS  is 
7increasing  in  countries  in  the  Asia–Pacific  region,  particularly  in 
countries with developing economies. Estimates of the prevalence of IBS 
(using theRome II  diagnostic  criteria)  vary widely in  the Asia–Pacific 
region. (2) In addition, comparisons of data from different regions are 
often problematic due to the use of different diagnostic criteria, as well as 
the influence of other factors such as population selection, inclusion or 
exclusion of co morbiddisorders (e.g., anxiety), access to health care, and 
cultural influences.
Several attempts have been made to define the diagnostic criteria 
for IBS. Each attempt implies shortcomings in the previous ones.
So  ,  is  the  new  questionnaire[2]  proposed  by  the  WGO  for 
diagnosis for Health Care Professionals to diagnose IBS.
Present  study  was  undertaken  to  find  the  usefulness  of  this 
questionnaire against the existing Rome III criteria.
8AIMS AND OBJECTIVES
1. To study the validity of the questionnaire in patients with IBS 
2. To compare against Rome III criteria.
3. To study the  usefulness in  delineating patients  with IBS and 
other bowel diseases like IBD, Colonic cancer when compared with 
Rome III criteria.
9REVIEW OF LITERATURE
Irritable  bowel  syndrome (IBS) is  important  because of  its  high 
prevalence, substantial morbidity, and enormous costs. [3] [4] [5]
The diagnosis of IBS rests on making a positive clinical diagnosis 
from the history; that tests often are not needed represents an important 
conceptual advance.[6] There is increasing evidence that at least a subset 
of IBS has an organic gastrointestinal tract basis. [7]
Some characteristics of IBS are: 
1. It is not known to be associated with  an increased risk for the 
development  of  cancer  or  inflammatory  bowel  disease,  or  with 
increased mortality. 
2. It generates significant direct and indirect health-care costs. 
3. No pathophysiological substrate has been demonstrated in IBS. 
4. A transition  of  IBS to,  and  overlap  with,  other  symptomatic 
gastrointestinal  disorders  (e.g.,  gastroesophageal  reflux   disease, 
dyspepsia, and functional constipation) may occur. 
5. The condition usually causes long-term symptoms. 
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6. May occur in episodes.  
7. Symptoms vary and may be meal-related.  
8. Symptoms  interfere  with  daily  life  and  social  functioning  in 
many patients. 
9. Symptoms sometimes seem to develop as a consequence of a 
severe intestinal infection or to be precipitated by major life events, 
or in a period of considerable stress. 
In general, there is a lack of recognition of the condition; many 
patients  with  IBS  symptoms  do  not  consult  a  physician  and  are  not 
formally diagnosed. IBS generates significant direct and indirect health-
care costs.
PATHOPHYSIOLOGY 
A number  of  different  mechanisms have  been implicated  in  the 
pathogenesis  of  IBS  including  abnormal  motility,  visceral 
hypersensitivity, low-grade inflammation, and stress. [5] [9] [10] Genetic 
factors  could modulate  the processing of  gut  signals  centrally  and the 
inflammatory  and  immune  responses  locally,  possibly  predisposing  to 
IBS. It  seems reasonable to postulate that for IBS to manifest,  several 
abnormalities  (multiple  “hits”)  may  need  to  occur.  Some  authors, 
therefore, conceptualize IBS as “a discrete collection of organic bowel 
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diseases,”[9] whereas other experts are concerned about “organification” 
of IBS because it may reduce the emphasis on the biopsychosocial model 
[12] [13] and imply that biologic factors are not sufficient to cause the 
disease. It seems likely in IBS that an understanding of the individual, 
including his or her psychosocial nature and response to environmental 
factors influences the expression of any biologic determinants. 
Regardless,  further major therapeutic advances in the field seem 
unlikely  to  occur  until  the  specific  biologic  basis  for  symptoms  is 
identified better.
1. ALTERED COLONIC AND SMALL BOWEL MOTILITY
2. VISCERAL HYPERSENSITIVITY
3. ABNORMAL GAS PROPULSION AND EXPULSION
4. LOCAL INFLAMMATION
5. FOOD INTOLERANCE AND ALLERGY [31,37]
6. ABNORMAL COLONIC FLORA AND BACTERIAL OVERGROWTH
7. CENTRAL DYSREGULATION
8. PSYCHOLOGICAL FACTORS [71,72]
9. GENETICS [14]
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Figure 2
Schematic  illustration  of  functional  organization  of  central 
neuroaxis inprocessing and modulation of visceral afferent signals. 
(A)  Hierarchical  organization  of  reflex  responses  to  visceral 
afferent stimuli.  (B) Modulation of visceral afferent input by cognitive 
and  emotional  factors  within  the  central  neuroaxis.  PAG, 
periaqueductalgrey;  RVLM,  rostroventrolateral  medulla; 
VMM,ventromedial medulla; ANS, autonomic nervous system; hypoth, 
hypothalamus; Amy, amygdala; orbFC, orbitofrontal cortex.
DIAGNOSIS OF IBS 
Clinical history 
In  assessing  the  patient  with  IBS,  it  is  important  not  only  to 
consider  the  primary  presenting  symptoms,  but  also  to  identify 
precipitating  factors  and  other  associated  gastrointestinal  and  extra 
gastrointestinal symptoms. It is vital also to seek and directly question for 
the presence of alarm symptoms. The history is critical and involves both 
the identification of  those features regarded as typical  of  IBS and the 
recognition of “red flags” that suggest alterative diagnoses. Accordingly, 
the patient should be asked about the following (features marked with an 
asterisk * are compatible with IBS):
13
1. The pattern of abdominal pain or discomfort:  
2. Chronic duration*  
3. Type of pain: intermittent* or continuous  
4. Previous pain episodes*  
5. Location  of  pain.  In  some  individuals,  pain  may  be  well-
localized (to the  lower quadrant of the abdomen, for example), 
while in others the pain location tends to move around.  
6. Relief with defecation or passing of flatus*  
7. Nocturnal pain is unusual and is considered a warning sign 
8. Other abdominal symptoms:  
• Bloating  
• Distension  
• Borborygmi  
• Flatulence  
9. Nature of the associated bowel disturbance:  
• Constipation  [65]
• Diarrhea  
14
10. Alternation 
11. Abnormalities of defecation:  
• Diarrhea for >2 weeks 
• Mucus in the feces  
• Urgency of defecation  
• Feeling of incomplete defecation  
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Other information from the patient’s history and important warning signs: 
1. Unintended weight loss 
2. Blood in stool 
3. Family history of:  
• Colorectal malignancy  
• Celiac disease  [24,25]
• Inflammatory bowel disease 
4. Fever accompanying lower abdominal pain 
5. Relation to menstruation 
6. Relation to Drug therapy  
7. Consumption of foods (especially milk),  artificial  sweeteners, 
dieting products, or alcohol  [17,18,19]
8. Visiting the (sub-)tropics 
9. Abnormal eating habits  
• Irregular or inadequate meals  
• Insufficient fluid intake  [23,24]
• Excessive fiber intake   
• Obsession with dietary hygiene[20,21] 
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10. Family history of IBS. IBS clearly aggregates within families, 
although its genetics are poorly understood 
11. Nature  of  onset  (sudden  onset  in  relation   to  exposure  to 
gastroenteritis suggests PI-IBS) 
PSYCHOLOGICAL ASSESSMENT
Psychological factors have not been shown to cause or influence 
the  onset  of  IBS  [66,  68].  IBS  is  not  a  psychiatric  or  psychological 
disorder. However, psychological factors may: 
- Play a role in the persistence and perceived severity of abdominal 
symptoms [69,70,71]
- Contribute to impairment in the quality of life and excessive use of 
health-care services 
The following may be useful in providing an objective assessment 
of psychological features: 
1. Hospital  Anxiety  and  Depression  Scale  (HADS).  This  is  a 
simple 14-item questionnaire to measure the level of anxiety and 
depression [71, 72]. 
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2. The  Sense  of  Coherence  (SOC)  test  can  be  used  to  identify 
patients  with  a  low  SOC  who  respond  to  cognitive  behavioral 
therapy [74, 75]. 
3. The Patient Health Questionnaire (PHQ-15). This is a 15-item 
questionnaire that helps identify the presence of multiple somatic 
symptoms (somatization).  The PHQ-15 should be validated in a 
given country before it is used in clinical practice in that location 
[73]. 
PHYSICAL EXAMINATION
A physical examination reassures the patient and helps to detect 
possible organic causes.   A general examination is carried out for signs of 
systemic disease. 
• Abdominal examination:   Inspection , Auscultation  , Palpation  
•  Examination of the perianal region:   Digital rectal examination
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IBS DIAGNOSTIC ALGORITHM
IBS diagnostic cascade 
Level 1 
1. History, physical examination, exclusion  of alarm symptoms, 
consideration of psychological factors 
2. Full blood count (FBC), erythrocyte sedimentation rate (ESR) 
or C-reactive protein (CRP), stool studies (white blood cells, ova, 
parasites, occult blood) 
3. Thyroid function, tissue transglutaminase (TTG) antibody 
4. Colonoscopy and biopsy 
5. Fecal inflammation marker (e.g., calprotectin) 
Level 2 
1. History, physical examination, exclusion  of alarm symptoms, 
consideration of psychological factors 
2. FBC, ESR or CRP, stool studies, thyroid function 
3. Sigmoidoscopy
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EVALUATION OF IBS
A diagnosis of IBS is usually suspected on the basis of the patient’s 
history and physical examination, without additional tests. Confirmation 
of  the  diagnosis  of  IBS  requires  the  confident  exclusion  of  organic 
disease in a manner dictated by an individual patient’s presenting features 
and characteristics.  In many instances (e.g.,  in young patients with no 
alarm features), a secure diagnosis can be made on clinical grounds alone 
[36, 37]. 
Diagnostic criteria (Rome III) 
1. Onset of symptoms at least 6 months before diagnosis 
2. Recurrent abdominal pain or discomfort  for > 3 days per month 
during the past 3 months 
3. At least two of the following features:  
• Improvement with defecation  
• Association with a change in frequency of stool  
• Association with a change in stool form 
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In clinical practice, whether in the setting of primary or specialist 
care, clinicians usually base a diagnosis of IBS on their evaluation of the 
whole patient (often over time) and consider a multiplicity of features that 
support  the diagnosis  (apart  from pain and discomfort  associated with 
defecation or change in stool frequency or form). 
Symptoms common in IBS and supportive of the diagnosis: 
• Bloating 
• Abnormal stool form (hard and/or loose) 
• Abnormal stool  frequency (less than three times per week or 
over three times per day) 
• Straining at defecation 
• Urgency 
• Feeling of incomplete evacuation 
• The passage of mucus per rectum 
Behavioral features helpful in recognizing IBS in general practice: 
• Symptoms present for > 6 months 
• Stress aggravates symptoms 
• Frequent consultations for nongastrointestinal symptoms 
• History of previous medically unexplained symptoms 
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• Aggravation after meals [28, 29]
• Associated anxiety and/or depression 
Non-colonic complaints that often accompany IBS: 
• Dyspepsia—reported in 42–87% of IBS patients 
• Nausea 
• Heartburn 
     Associated non-gastrointestinal symptoms: 
• Lethargy 
• Backache and other muscle and joint pains 
• Headache 
Urinary symptoms:  
• Nocturia  
• Frequency and urgency of micturition  
• Incomplete bladder emptying 
Other non specific symptoms include:
• Dyspareunia, in women 
• Insomnia 
• Low tolerance to medication 
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Additional tests or examinations: 
In the majority of cases of IBS, no additional tests or examinations 
are  required.  An  effort  to  keep  investigations  to  a  minimum  is 
recommended in straightforward cases of IBS, and especially in younger 
individuals. 
HISTORY OF THE CRITERIA
1978     Manning et al., found, from questionnaire data, that IBS 
sufferers  reported four  common symptoms.  The Manning Criteria was 
established  to  distinguish  organic  causes  for  symptoms from those  of 
IBS. 
1992     Rome  I  Criteria  was  established  by  a  multinational 
committee of specialists, which further refined the Manning Criteria. 
1998    Rome Working Team proposed changes to the definition 
and  diagnostic  criteria  for  IBS  to  reflect  new  research  data,  and  to 
improve clarity. They produced the Rome II Criteria. 
 2006   Rome II  criteria was further  defined by the expanded 
Rome Working Team into what is now known as the Rome III Criteria.
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Table 1 -- Comparison of the Major Diagnostic Criteria for the 
Irritable Bowel Syndrome
Manning 
Criteria
Rome I Criteria Rome II Criteria Rome III criteria
• Abdominal 
pain that is 
relieved after 
a bowel 
movement
≥3mo  of  continuous 
or  recurrent 
symptoms  of 
abdominal  pain  or 
discomfort  relieved 
with  defecation  or 
associated  with 
change  in  frequency 
or consistency of stool 
and  Disturbed 
defecation (≥ 2 of the 
following): 
≥12wk,  which 
need  not  be 
consecutive,  in 
the  preceding 
12mo  of 
abdominal 
discomfort  or 
pain  that  has  at 
least  2  of  the  3 
following 
features: 
At least 3 months, 
with onset  at  least 
6  months 
previously  of 
recurrent 
abdominal  pain  or 
discomfort 
associated  with  2 
or  more  of  the 
following:
• Looser 
stool at pain 
onset
•  Altered  stool 
frequency                    
•  Relieved  with 
defecation    
•  Improvement 
with  defecation; 
and/or
• More 
frequent 
stools at pain 
onset
•  Altered  stool  form 
(hard or loose/watery) 
• Onset associated 
with  a  change  in 
frequency of stool
•  Onset  associated 
with  a  change  in 
frequency of stool; 
and/or
• Abdominal 
distention 
(visible)
•  Altered  stool 
passage  (straining  or 
urgency,  feeling  of 
incomplete 
evacuation)
• Onset associated 
with  a  change  in 
stool form
•  Onset  associated 
with  a  change  in 
form  (appearance) 
of stool
• Sensation 
of 
incomplete 
rectal 
evacuation
• Passage of mucus 
• Passage of 
mucus
•  Bloating  or  feeling 
of  abdominal 
distention
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According to the Rome III criteria, and  on the basis of the patient’s 
stool characteristics: 
•  IBS with diarrhea (IBS-D):  
— Loose stools > 25% of the time and hard stools < 25% of the time  
— Up to one-third of cases  
— More common in men 
•  IBS with constipation (IBS-C):  
— Hard stools > 25% of the time and loose stools < 25% of the time  
— Up to one-third of cases  
— More common in women
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DIFFERENTIAL DIAGNOSIS
1. Celiac sprue/ gluten enteropathy [24, 26]
• Chronic diarrhea 
• Failure to thrive (in children) 
• Fatigue 
• Estimated to affect ± 1% of all Indo-European populations 
• To be considered in the differential diagnosis in regions of high 
prevalence 
2. Lactose intolerance 
• Symptoms  (bloating,  flatulence,  diarrhea)  acutely  related  to 
consumption of dairy products [32, 33, 34, 35]
• Can  be  identified  by  a  lactose  breath  hydrogen  test,  after  a 
positive milk-drink test 
3. Inflammatory bowel disease (Crohn's disease, ulcerative colitis) 
• Diarrhea has persisted for > 2 weeks 
• Rectal bleeding 
• Inflammatory mass, weight loss, perianal disease, fever
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4. Colorectal carcinoma 
• Older  patients  who develop  IBS-type  symptoms for  the  first 
time 
• Passage of blood in the feces 
• Unintended weight loss 
• Pain may be obstructive in type for left-sided lesions 
• Anemia or iron deficiency for right-sided lesions 
5. Lymphocytic and collagenous colitis 
• Accounts for 20% of unexplained diarrhea in patients over 70 
years of age.
• Typically painless
• Most common in middle-aged females 
• Diagnosed on colonic biopsies [52, 53]
6. Acute diarrhea due to protozoa or bacteria 
• Acute onset of diarrhea [38, 39, 40]
• Stool examination or duodenal biopsy
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7. Small-intestinal bacterial overgrowth (SIBO) 
• The classical features of SIBO are those of maldigestion and 
malabsorption [41, 43]. 
• Some  of  the  symptoms  of  SIBO  (bloating,  diarrhea)  may 
overlap with those of IBS, which has led to the suggestion that 
SIBO is common in IBS [42]. 
• The bulk of evidence suggests that SIBO is not common in IBS. 
8. Diverticulitis 
The relationship between IBS and so-called “painful  diverticular 
disease”  is  unclear  [44,  45].  In  diverticulitis,  the  classical 
symptoms  and/or  findings  are  episodic  and  acute  to  subacute 
during an episode, featuring:
• Left-sided abdominal pain 
• Fever 
• Tender inflammatory mass in the left lower quadrant
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9. Endometriosis 
• Cyclical lower abdominal pain 
• Enlarged  ovaries  or  nodules  dorsal  to  the  cervix  (on  digital 
vaginal examination) 
10. Pelvic inflammatory disease 
• Non acute lower abdominal pain 
• Fever 
• Upward  pressure  pain  or  adnexal  tenderness  and  swollen 
adnexa (on digital vaginal examination) 
11. Ovarian cancer 
• Abdominal size 
• Bloating 
• Urinary urgency 
• Pelvic pain
29
MATERIALS AND METHODS
This  study  is  an  analytical  study  conducted  in  a  major  public 
hospital  from June 2009 to September 2009 and included a total of 52 
patients.  The  reference  population  is  Tamil  speaking  population 
belonging to lower and low middle socio – economic status attending 
government hospitals. The study population was taken from the Medical 
Gastroenterology out patient department and wards.
Inclusion criteria
Males and females with chronic abdominal pain / discomfort with 
duration of >3 months associated with disturbed defecation.
Exclusion criteria
1. Those with known Ulcerative Colitis
2. Those with known Crohn’s disease
3. Those with known thyroid dysfunction.
4. Those with known abdominal malignancy.
5. Those with known abdominal tuberculosis
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6. Pregnant women
The  questionnaire  released  by  the  World  Gastroenterology 
Organization consists of 21 questions with points for questions 1 -16. 
The questions were translated into Tamil with the help of a team 
consisting  of  two  non  medicos  with  proficiency  in  Tamil,  two  non 
medicos with proficiency in English and two medicos.
The questions were asked from the Tamil version to patients. And 
literate persons who volunteered to fill the questionnaire themselves were 
also encouraged to do so.
A standardized  pro  forma  was  used  to  cover  the  subject’s  age, 
education,  duration  of  illness,  past  medical  &  surgical  illness  and 
concurrent  medications.  Also  included  were  history  of  upper  GI 
symptoms like bloating, dyspepsia & nausea. History of passing worms 
in stools was also elicited.
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PHYSICAL EXAMINATION
Physical examination included:
i. Measurement of height/ weight and calculation of BMI using 
the formula Ht in m2/wt in kg
ii. Pulse rate and blood pressure
iii. General examination
iv. Examination of  Abdomen
v. Other system examination
INVESTIGATIONS
i. Complete  blood  count Total  count,  differential  count  , 
Hemoglobin%, Platelet count, PCV, ESR
ii. Fasting Blood sugar
iii. Stool examination for ova, cyst, blood
iv. Urine analysis
v. Serum TSH
vi. ELISA HIV
vii. Ultrasound Abdomen
viii. Colonoscopy
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DEFINING CRITERIA 
i. Duration for minimum 3 months
ii. Altered stool frequency
iii. Altered stool consistency
iv. Altered stool form
v. Abdominal discomfort, improving with defecation
vi. No red flag sign bleeding PR, weight loss,  loss of appetite, 
sleep  disturbance
vii. Normal colonoscopy 
viii. Normal TSH
ix. ELISA HIV Negative
x. Normal Fasting Blood sugar (<100 mg/ dl)
Based on the above criteria patients were confirmed to have IBS
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OBSERVATION AND RESULTS
Total no of Patients 52
Those with IBS 46
Those without IBS 6
ROME III CRITERIA
Those fulfilling ROME III Criteria 50
Those not  fulfilling ROME III Criteria 2
QUESTIONNAIRE
Total no of patients with a likely score 6
Total no of patients with possible score 38
Total no of patients with an unlikely  score 8
ANALYSIS OF ROME III CRITERIA
True Positives 45
True Negatives 1
False Positives 5
False Negatives 1
Total no of patients 52
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ROME III CRITERIA
ROME CRITERIA Those with IBS Those without IBS
Positive 46 6
Negative 1 1
Sensitivity = 97.8%
Specificity = 14.28%
Predictive value of a positive test = 88.46%
Predictive value of a negative test = 50%
Percentage of false positives = 85.7%
Percentage of false negatives = 2.12%
ANALYSIS OF QUESTIONNAIRE
True Positives 43
True Negatives 5
False Positives 1
False Negatives 3
Total no of patients 52
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QUESTIONNAIRE
QUESTIONNAIRE Those with IBS Those without IBS
Positive 43 1
Negative 3 5
Sensitivity = 93.4%
Specificity = 83.3%
Predictive value of a positive test = 97.72%
Predictive value of a negative test = 62.5%
Percentage of false positives =16.6%
Percentage of false negatives = 6.52%
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COMPARISION OF SENSITIVITIES OF ROME III CRITERIA & 
QUESTIONNAIRE
Sensitivity of Questionnaire 93.40%
Sensitivity of Rome III 97.80%
COMPARISION OF SPECIFICITIES OF ROME III CRITERIA & 
QUESTIONNAIRE
Specificity of Questionnaire 83.30%
Specificity of Rome III 14.28%
COMPARISION OF PREDICTIVE VALUE OF A POSITIVE TEST 
OF ROME III CRITERIA & QUESTIONNAIRE
Predictive value of a positive test  of Questionnaire 97.72%
Predictive value of a positive test  of Rome III 88.46%
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COMPARISION OF PERCENTAGE OF FALSE POSITIVES WITH 
ROME III CRITERIA & QUESTIONNAIRE
Percentage of false positives of Questionnaire 16.6%
Percentage of false positives  of Rome III 85.7%
COMPARISION OF PERCENTAGE OF FALSE NEGATIVES 
WITH ROME III CRITERIA & QUESTIONNAIRE
Percentage of false negatives of Questionnaire 6.52%
Percentage of false negatives of Rome III 2.12%
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DISCUSSION
Out of 52 patients who were taken up for final statistical analysis , 
the prevalence of IBS was 88% and 12% had other organic diseases.
Fifty  patients  were  diagnosed  to  be  IBS  when  the  ROME  III 
criteria was applied. But of them only 45 were truly IBS. 5 patients had 
organic bowel disease. One patient with IBS did not fit into the criteria of 
ROME III. And one patient with drug related constipation was correctly 
diagnosed by the ROME III criteria as non –IBS.
The  questionnaire  was  a  quantitative  and  qualitative  assessment 
when  compared  to  the  Rome.  It  quantitated  the  relation  between 
abdominal pain with bowel movements, bloating sensation and flatulence 
and also their interaction with activities of daily life. Also the addition of 
age, and giving a score of 0 for > 50 yrs of age makes it advantageous in 
the context of colonic cancer.
When the questionnaire was asked to patients, those with a likely 
score  of  25  –  30  were  6  in  number.  All  six  patients  had  normal 
colonoscopic findings and normal lab findings.
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And  the  number  of  patients  with  a  score  15-24,  where  IBS  is 
possible although other conditions are also possible was 37.  Amongst 
them one patient had colitis.
And those with a score <15 which is suggestive of non-IBS were 8. 
Amongst them 5 patients were non – IBS, the causes being hemorrhoids, 
Ulcerative colitis, Crohn’s disease and non specific Colitis. 3 patients had 
normal colonoscopic and lab findings suggestive of IBS. 
Comparing  this  questionnaire  with  ROME  III  criteria,  the 
sensitivity of Rome (97%) was slightly higher than questionnaire (93%). 
The  specificity  was  much  higher  for  questionnaire  (83%)  than  Rome 
(14%).  The predictive value of a positive test and negative test  were 
definitely higher with the questionnaire (98% and 62%) as against  the 
Rome (88% and 50%). The percentage of false positives was low with 
questionnaire  (16%)  against  (86%)  Rome.  The  percentage  of  false 
negatives  was  only  slightly  higher  in  questionnaire  (6%)  than  Rome 
(2%).
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 The additional non scoring questions in this questionnaire which 
were not included in the ROME III criteria were:
1. Family history of colonic cancer / celiac disease /IBS.
2. Recent treatment with antibiotics.
3. Unintentional weight loss.
4. Blood on stools.
5. Nocturnal symptoms
One patient had a family history (elder brother) had colonic cancer. 
Two patients with IBS were 50 yrs father and 18 yrs old son. And one 
patient’s mother had IBS.
Only one patient gave a history of recent treatment with antibiotics 
for upper respiratory tract infection.
Weight  loss was  given by 5 patients  with IBS,  of  whom 4 had 
diarrhea predominant IBS and 1 had constipation predominant IBS. Only 
one patient with IBD reported weight loss. 
Regarding  blood  loss  in  stools,  almost  90  % patients  with  IBS 
reported passing blood in stools at some point. And all non IBS patients 
including those who had drug related constipation had blood loss in stool.
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In  one  study  by  Cash,  Schoenfeld  and  Chey,  the  investigators 
identified  that  the  alarm  features  of  age  greater  than  50  years  and 
hematochezia were independent predictors of lower GI organic disease. 
Most importantly, they found that symptom-based diagnostic accuracy for 
differentiating  between  IBS  and  organic  disease  was  enhanced  when 
alarm features were considered along with non-alarm features (such as 
gender and pain frequency and severity) and the Manning criteria.
 This is contrasting to our Indian population where most patients 
with IBS report having passed blood in stools.  But at the time of this 
study, the stool examination did not reveal blood.
And  70  % patients  had  threadworms  in  stool.   But  their  stool 
examination was inconclusive, except for 3 patients who had E.histolytica 
in stool. 
Sleep disturbance  in the form of nocturnal diarrhea was present in 
21 IBS patients. 4 non IBS patients had sleep disturbances.
42
LIMITIATIONS OF STUDY
1. Tissue  Transglutaminase   antibodies  were  not  done  which 
would help to identify celiac disease.
2. CRP would have been a better inflammatory marker than ESR.
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SUMMARY AND CONCLUSIONS
1. Comparing  this  questionnaire  with  ROME  III  criteria  ,  the 
sensitivity  of  Rome(97%)  was  slightly  higher  than 
questionnaire(93%). 
2. The  specificity  was  much  higher  for  questionnaire(83%)  than 
Rome ( 14%).
3.    The  predictive  value  of  a  positive  test  and  negative  test  were 
definitely higher with the questionnaire(98% and 62%) as against 
the Rome (88% and 50%).
4. The  percentage  of  false  positives  was  low  with  questionnaire 
(16%) against (86%) Rome.
5. The  percentage  of  false  negatives  was  only  slightly  higher  in 
questionnaire (6%) than Rome (2%).
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Thus it is concluded that,
The new questionnaire is definitely useful in identifying patients 
with IBS.
Also it is more specific for IBS, reducing the need for invasive and 
costly procedures.
And with this questionnaire the disadvantage of missing organic 
bowel disease is eliminated making this recommendable in patients with 
bowel disturbance of all age group. 
And this questionnaire can be used by primary care physicians and 
also paramedical  staff  and thereby guide those patients  who will  need 
further assessment by a Gastroenterologist.
Therefore, the new questionnaire released by the WGO is better 
than the currently existing Rome III criteria.
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                                       ABBREVIATIONS
IBS – Irritable bowel syndrome
IBD – inflammatory bowel disease
TSH – thyroid stimulating hormone
HIV – human immunodeficiency virus
PAG –peri aqueductal grey 
RVLM- rostro ventro lateral medulla
VMM –ventro medial medulla
ANS - autonomic nervous system 
HCP –Health care professional
WGO – World Gastroenterology Organization
ISG – Indian Society of Gastroenterology
HADS -Hospital Anxiety and Depression Scale  
SOC -Sense of Coherence
PHQ- Patient Health Questionnaire 
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                                                                    PRO FORMA
Name :                                                           Age :                    Sex:           Marital Status:
Occupation:                                                 Income :                                        Education:
Address:
Duration of illness:
Past hisrory:                  DM                       SHT                         CAD                        TB
Drug history:
History of :    1. Dyspepsia
                       2. Heartburn 
                       3 . Nausea 
                      4. Worms in stool
                      5. Abdominal surgery
Diet :      veg                         Non – veg
Precipitant meal :
Habits : smoking              alcohol                 tobacco                  betel nut
PR                BP                  Ht                    Wt                         BMI
Per Abdomen
Per Rectum
Investigations
4. CBC  : Hb       TC              DC                    ESR              PCV                    Pl. 
count
5. Stool : ova                     cyst                              blood
6. Serum TSH 
7. ELISA  HIV
8. USG ABDOMEN
9. Random Blood Sugar                                         
10. Urine : Sug                     alb                         dep
11. Colonoscopy
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12. Biopsy
13. Score          :                                   IBS questionnaire                                   ROME 
III 
